CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTS
Introduction. Possibilities of using probiotic enterococci in premature neonates undergoing inpatient antibacterial therapy remains understudied. The article is aimed at analyzing clinical and pharmacoeconomic reasonability of using probiotic Enterococcus faecium L3 strain in premature infants with...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2015-08-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849685709073416192 |
|---|---|
| author | N. V. Gonchar L. A. Lo Schiavo A. N. Suvorov N. P. Shabalov A. S. Kolbin A. P. Kasimova |
| author_facet | N. V. Gonchar L. A. Lo Schiavo A. N. Suvorov N. P. Shabalov A. S. Kolbin A. P. Kasimova |
| author_sort | N. V. Gonchar |
| collection | DOAJ |
| description | Introduction. Possibilities of using probiotic enterococci in premature neonates undergoing inpatient antibacterial therapy remains understudied. The article is aimed at analyzing clinical and pharmacoeconomic reasonability of using probiotic Enterococcus faecium L3 strain in premature infants with very low body weight in the framework of complex inpatient developmental care. Patients and methods. 55 children randomized into 2 groups were observed: the control group (n = 26) was undergoing standard developmental care program, the primary group (n = 29) was introduced liquid probiotic Enterococcus faecium L3 strain (titer — 108 CFU/ml or more) (0.5 ml TID for 14 days) after attaining the enteral feeding volume of 5.0 ml. Results. Analysis of the clinical symptoms characteristic of non-smooth course of developmental care over premature infants helped to reveal higher frequency of infectious complications in the control group children than in the primary group (14 [53.8%] vs. 6 [20.7%]; p < 0.05). Acute food intolerance was observed less frequently in the primary group than in the control group (6 [20.7%] vs. 10 [38.5%], p > 0.05). The primary group's children featured significant decrease in the frequency of monocytosis, positive changes of intestinal microbiotic composition (increase in the amount of bifidum bacteria, lactobacilli, enterococci, decrease in the amount of Clostridium difficile and antibiotic-resistant clinical Klebsiella pneumoniae strains). Conclusion. Favorable outcome of developmental care over premature infants (absence of infectious complications) was less expensive in the primary group's children. |
| format | Article |
| id | doaj-art-7b3a7735c56c4210a116c09ee012c280 |
| institution | DOAJ |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2015-08-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-7b3a7735c56c4210a116c09ee012c2802025-08-20T03:23:01ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892015-08-01121222910.15690/pf.v12i1.1243455CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTSN. V. Gonchar0L. A. Lo Schiavo1A. N. Suvorov2N. P. Shabalov3A. S. Kolbin4A. P. Kasimova5Mechnikov North-Western State Medical University, Saint Petersburg, Russian Federation Scientific Research Institute of Childhood Infections of the Russian Federal Biomedical Agency, Saint Petersburg, Russian FederationMunicipal Pediatric Hospital No. 1, Saint Petersburg, Russian FederationScientific Research Institute of Experimental Medicine, North-Western branch of the Russian Academy of Medical Sciences, Saint Petersburg, Russian Federation Saint Petersburg State University, Russian FederationKirov Military Medical Academy of the Ministry of Defense of the Russian Federation, Saint PetersburgAcademician Pavlov First Saint Petersburg State Medical University, Russian FederationAcademician Pavlov First Saint Petersburg State Medical University, Russian FederationIntroduction. Possibilities of using probiotic enterococci in premature neonates undergoing inpatient antibacterial therapy remains understudied. The article is aimed at analyzing clinical and pharmacoeconomic reasonability of using probiotic Enterococcus faecium L3 strain in premature infants with very low body weight in the framework of complex inpatient developmental care. Patients and methods. 55 children randomized into 2 groups were observed: the control group (n = 26) was undergoing standard developmental care program, the primary group (n = 29) was introduced liquid probiotic Enterococcus faecium L3 strain (titer — 108 CFU/ml or more) (0.5 ml TID for 14 days) after attaining the enteral feeding volume of 5.0 ml. Results. Analysis of the clinical symptoms characteristic of non-smooth course of developmental care over premature infants helped to reveal higher frequency of infectious complications in the control group children than in the primary group (14 [53.8%] vs. 6 [20.7%]; p < 0.05). Acute food intolerance was observed less frequently in the primary group than in the control group (6 [20.7%] vs. 10 [38.5%], p > 0.05). The primary group's children featured significant decrease in the frequency of monocytosis, positive changes of intestinal microbiotic composition (increase in the amount of bifidum bacteria, lactobacilli, enterococci, decrease in the amount of Clostridium difficile and antibiotic-resistant clinical Klebsiella pneumoniae strains). Conclusion. Favorable outcome of developmental care over premature infants (absence of infectious complications) was less expensive in the primary group's children.https://www.pedpharma.ru/jour/article/view/459premature infantsvery low birth weightantibiotic therapyprobiotic enterococcus strainpharmacoeconomic reasonability |
| spellingShingle | N. V. Gonchar L. A. Lo Schiavo A. N. Suvorov N. P. Shabalov A. S. Kolbin A. P. Kasimova CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTS Педиатрическая фармакология premature infants very low birth weight antibiotic therapy probiotic enterococcus strain pharmacoeconomic reasonability |
| title | CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTS |
| title_full | CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTS |
| title_fullStr | CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTS |
| title_full_unstemmed | CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTS |
| title_short | CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTS |
| title_sort | clinical and pharmacoeconomic reasonability of using probiotic enterococcus strain for the complex developmental care program for premature infants |
| topic | premature infants very low birth weight antibiotic therapy probiotic enterococcus strain pharmacoeconomic reasonability |
| url | https://www.pedpharma.ru/jour/article/view/459 |
| work_keys_str_mv | AT nvgonchar clinicalandpharmacoeconomicreasonabilityofusingprobioticenterococcusstrainforthecomplexdevelopmentalcareprogramforprematureinfants AT laloschiavo clinicalandpharmacoeconomicreasonabilityofusingprobioticenterococcusstrainforthecomplexdevelopmentalcareprogramforprematureinfants AT ansuvorov clinicalandpharmacoeconomicreasonabilityofusingprobioticenterococcusstrainforthecomplexdevelopmentalcareprogramforprematureinfants AT npshabalov clinicalandpharmacoeconomicreasonabilityofusingprobioticenterococcusstrainforthecomplexdevelopmentalcareprogramforprematureinfants AT askolbin clinicalandpharmacoeconomicreasonabilityofusingprobioticenterococcusstrainforthecomplexdevelopmentalcareprogramforprematureinfants AT apkasimova clinicalandpharmacoeconomicreasonabilityofusingprobioticenterococcusstrainforthecomplexdevelopmentalcareprogramforprematureinfants |